Chongqing Lummy Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 441.76 million compared to CNY 397.38 million a year ago. Revenue was CNY 453.86 million compared to CNY 406.43 million a year ago.

Net loss was CNY 54.06 million compared to CNY 49.07 million a year ago. Basic loss per share from continuing operations was CNY 0.0512 compared to CNY 0.0465 a year ago. Diluted loss per share from continuing operations was CNY 0.0512 compared to CNY 0.0465 a year ago.